Immuron Successfully Completes NASH Phase II Clinical Study Milestone
09 nov. 2017 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...